



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/584,113

04/04/2007

Kristian Lund Henriksen

BECK:001

3904

36275

7590

10/28/2009

O'KEEFE, EGAN, PETERMAN & ENDERS LLP
1101 CAPITAL OF TEXAS HIGHWAY SOUTH
#C200
AUSTIN, TX 78746

EXAMINER

SCHUBERG, LAURA J

ART UNIT

PAPER NUMBER

1657

MAIL DATE

DELIVERY MODE

10/28/2009

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No. 10/584,113	Applicant(s) HENRIKSEN ET AL.	
	Examiner Laura Schuberg	Art Unit 1657	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 24 July 2009.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-50 is/are pending in the application.
- 4a) Of the above claim(s) 12-18,27-31,and 49 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-11,19-26,32-48 and 50 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☒ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☒ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date <u>12/11/06</u> . | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Applicant is requested to note that the Examiner for this application has changed. Future correspondence should be directed to Laura Schuberg, Art Unit 1657, whose contact information can be found below.

Election/Restrictions

Applicant's election with traverse of specie iron for the secondary ingredient in the reply filed on 07/24/2009 is acknowledged. The traversal is on the ground(s) that the species have unity of invention as evidenced during the international PCT phase of prosecution and every patent office where the application was nationalized except for the USPTO. Applicant asserts that the Examiner has not provided sufficient reasoning or justification for the election of species requirement.

This is not found persuasive because the numerous ingredients claimed by Applicant for inclusion as secondary ingredients are not art recognized equivalents as they do not share a common structural or technical feature that would render them so. When the Examiner states that these species are distinct, what is meant that they are not art recognized equivalents and as such an artisan of ordinary skill in the art would not be motivated to substitute one for the other based on a common technical or structural feature.

In addition, PCT prosecution does not bind US patent examination and prosecution. On the international level, all written opinions are nonbinding and a patent

Art Unit: 1657

does not issue; what does issue is an international preliminary examination report (IPER), which is nonbinding on the Elected States. See M.P.E.P. § 1878.01, Item V.

Also other patent offices may choose to examine all species regardless of their status, this does not require the US patent office to do so as well as long as the species are patentably distinct.

The requirement is still deemed proper and is therefore made FINAL.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Claims 1-50 are pending.

Claims 12-18, 27-31 and 49 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected specie, there being no allowable generic or linking claim.

Claims 1-11, 19-26, 32-48 and 50 have been examined on their merits.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 1, 3-11, 19-26, 33-39, 4-44, 46 and 47 are rejected under 35 U.S.C. 103(a) as being unpatentable over Giagau et al (DE 10206995 machine translation) in view of Runge et al (WO 99/57242-using US 7,037,708 as translation).

Claim 1 is drawn to a probiotic tablet comprising at least two zones wherein the first zone comprises a probiotic and a second zone comprises at least one other active ingredient kept separate from the probiotic in the first zone and wherein the water activity of the probiotic in the first zone is no greater than 0.2 and the water content of the tablet being no less than 0.2% by weight.

Dependent claims include wherein the first zone is free from amounts deleterious to the viability of the probiotic of several ingredients (claims 3-10), wherein the second zone contains iron as an active ingredient (claims 11 and 19), the addition of a desiccant carrier material (claims 20-22), a multi-layer structure (claim 23), first zone free of encapsulated iron, zinc and copper (claims 24-26), specific water contents (claims 33-39), specific water activity (claims 40-44), including a coating that excludes water (claim 46) and wherein the tablet is stored under specific conditions (claim 47).

Giagau et al teach a two-part micronutrient product, useful as a dietary supplement and for treatment of disease which comprises a probiotic component in a first zone and secondary ingredients in a second zone (abstract). The product may be formulated as multi-component single tablet (page 1, 5th paragraph) wherein the first and second zone are kept separate from each other (page 2, 5th paragraph). The second portion is taught to potentially contain many different secondary ingredients and includes combinations of iron and vitamins B6 and C (page 8). Adjuvants to be added to the probiotic in the first zone include starch (page 8 example 1) and other ingredients that improve the bioavailability and shelf life of the probiotic (page 6, 1st paragraph). The

Art Unit: 1657

first zone is kept free of amounts of any substances that are deleterious to the viability of the probiotic.

Giagau et al are silent with regard to the water content and water activity of the probiotic composition.

Runge et al teach dried microorganism cultures that are compressed and used for foodstuffs and feedstuffs (abstract). Preferred probiotics include *Lactobacillus* sp. As well as other genera (column 6 lines 19-44 of US 7,037,708). Dry preparations having low moisture content (of from about 2 to 3% by weight of water) corresponding to a water activity of from 0.03 to 0.15 are provided by spray drying and have survival rates of up to 60% after storage for 1 year at ambient temperatures and ambient air conditions (column 5 lines 10-21). Tablet formulations of the dried microorganisms are taught as suitable and include the addition of tableting aids such as PVP (column 11 lines 47-67) and desiccants (column 10 lines 8-18). Coating materials are added to hinder the ingress of moisture to the dry preparation (column 12 lines 24-26). Storage in suitable containers is taught as well (column 18 lines 1-10).

It would have been obvious to apply the formulation methods of Runge et al to the tableted probiotic composition of Giagau et al with regard to the water content, water activity and suitable additives of the different zones. One of ordinary skill in the art would have been motivated to do so because Runge et al teach that these parameters are beneficial to the viability and shelf life of a dried probiotic composition. Modifying the water activity to 0.02 would have been a matter of routine optimization and experimentation as the artisan of ordinary skill would be motivated to attain a dry

Art Unit: 1657

microorganism with the greatest stability and viability. The use of a storage container with a desiccant would have also been obvious as Runge et al teach the benefit of adding desiccant materials and storing the product in suitable storage containers as well. One of ordinary skill in the art would have had a reasonable expectation of success because both Giagau et al and Runge et al are producing tableted probiotic compositions for oral administration.

Therefore the combined teachings of Giagau et al and Runge et al render obvious Applicant's invention as claimed.

Claim 2 is rejected under 35 U.S.C. 103(a) as being unpatentable over Giagau et al (DE 10206995 machine translation) in view of Runge et al (WO 99/57242-using US 7,037,708 as translation) as applied to claims 1, 3-11, 19-26, 33-39, 4-44, 46 and 47 above, and further in view of Belicova et al (Folia Microbiol. 2004).

Claim 2 includes wherein the first zone also contains selenium as an additional active agent.

The combined teachings of Giagau et al and Runge et al render obvious the claimed invention as described above, but do not specifically include wherein selenium is included in the first zone with the probiotic component.

Belicova et al teach that the antimutagenic activity of probiotic bacterium *Enterococcus faecium* was enhanced by the addition of selenium. Selenium enriched

Art Unit: 1657

probiotic bacterium *E. faecium* can be considered as a food supplement with beneficial health benefits (page 304, last paragraph).

Therefore it would have been obvious to include selenium in the first zone with the probiotic component of the Giagau et al composition because Belicova et al teach that selenium enhances the antimutagenic activity of probiotic bacterium *Enteroccus faecium* and selenium enriched probiotic bacterium *E. faecium* can be considered as a food supplement with beneficial health benefits (page 304, last paragraph). One of ordinary skill in the art would have had a reasonable expectation of success because Giagau et al were also using the probiotic bacterium *Enteroccus faecium* as well (page 2, last paragraph).

Therefore the combined teachings of Giagau et al, Runge et al and Belicova et al render obvious Applicant's invention as claimed.

Claims 32, 45, and 48 are rejected under 35 U.S.C. 103(a) as being unpatentable over Giagau et al (DE 10206995 machine translation) in view of Runge et al (WO 99/57242-using US 7,037,708 as translation) as applied to claims 1, 3-11, 19-26, 33-39, 4-44,46 and 47 above, and further in view of Andoh et al (EP 0255725) and Bakulesh et al (GB 2323532- from IDS).

Claim 32 includes wherein the tablet has a multitude of granules constituting the first zone surrounded by a matrix, and wherein the matrix constitutes a second zone **or** wherein the matrix also contains a multitude of granules constituting the second zone.

Claim 45 includes water excluding barrier material surrounding the first zone of the tablet.

Claim 48 includes wherein the barrier material is a fat or wax based material.

The combined teachings of Giagau et al and Runge et al render obvious the claimed invention as described above, but do not specifically include a formulation that includes zones of matrix and compressed granules, or barrier materials between the zones. However, Giagau et al do indicate that additives that offer an improvement or benefit to the final product formulation may be included (page 6).

Andoh et al teach a sustained release multi-granule tablet useful in the field of therapy. The invention is concerned with a tablet of the multiple unit type (different zones) in which sustained release granules are contained as a unit (page 2, 1st paragraph). Water resistant coatings (barriers) are applied in layers between the different zones (page 3).

Bakulesh et al teach a method of making a pharmaceutical formulation of a probiotic that is kept separate from secondary active ingredients by the addition of barrier materials (page 13). Exemplary barrier materials are taught to include oil/wax based materials (page 15, number 9).

Therefore one of ordinary skill in the art would have been motivated with a reasonable expectation of success to apply the formulation strategies of Andoh et al or

Art Unit: 1657

Balulesh et al to the probiotic tablets of Giagau et al because Andoh et al and Bakulesh et al teach that these are suitable for the formulation of multi-component tablets for pharmaceutical use.

Therefore the combined teachings of Giagau et al, Runge et al, Andoh et al and Bakulesh et al render obvious Applicant's invention as claimed.

Claim 50 is rejected under 35 U.S.C. 103(a) as being unpatentable over Giagau et al (DE 10206995 machine translation) in view of Runge et al (WO 99/57242-using US 7,037,708 as translation) as applied to claims 1, 3-11, 19-26, 33-39, 4-44,46 and 47 above, and further in view of Cavaliere et al (EP 0956858- from IDS).

Claim 50 includes wherein the first zone disintegrates at a faster rate than the second zone and is no more than 50% of the total disintegration time.

The combined teachings of Giagau et al and Runge et al render obvious the claimed invention as described above, but do not specifically include different disintegration times of the different zones. Giagau et al do indicate that additives that offer an improvement or benefit to the final product formulation may be included (page 6) and Runge et al indicate that formulating the product to allow for a more rapid release of the microorganism is suitable as well (column 11 lines 7-45).

Cavaliere et al disclose a two-layer tablet comprising a quick release layer and a slow release layer, both containing a dried probiotic culture. The quick release layer

Art Unit: 1657

disintegrates in a lapse of time of 10-25 minutes whereas the slow release layer disintegrates in a lapse of time of 25-50 minutes (page 4 paragraphs 28-29).

Therefore one of ordinary skill in the art would have been motivated with a reasonable expectation of success to apply the formulation strategies of Cavaliere et al to the probiotic tablets of Giagau et al because Cavaliere et al teach that these are suitable for the formulation of multi-component probiotic tablets for pharmaceutical use.

Modifying the release characteristics of the tablet in order to optimize the therapeutic result would have been a matter of routine optimization and experimentation, the artisan of ordinary skill motivated to release the probiotics in a manner that increases the effectiveness of the probiotic microorganisms.

Therefore the combined teachings of Giagau et al, Runge et al, and Cavaliere et al render obvious Applicant's invention as claimed.

Conclusion

No claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Laura Schuberg whose telephone number is (571)272-3347. The examiner can normally be reached on Mon-Fri 8:00-4:30.

Art Unit: 1657

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jon Weber can be reached on (571) 272-0925. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Laura Schuberg

/JON P WEBER/

Supervisory Patent Examiner, Art Unit 1657